Skip to main content
Article thumbnail
Location of Repository

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

By R Fleischmann, J Vencovsky, R F van Vollenhoven, D Borenstein, J Box, G Coteur, N Goel, H-P Brezinschek, A Innes and V Strand
Topics: Clinical and Epidemiological Research
Publisher: BMJ Publishing Group
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
  2. (1999). A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
  3. (1995). American College of Rheumatology. Preliminary definition of improvementi n rheumatoid arthritis. Arthritis Rheum
  4. (2006). Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register. Arthritis Res Ther
  5. Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis.
  6. (2004). Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis
  7. (2009). Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. Ann Rheum Dis
  8. (1999). Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial.
  9. Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther 2003;5:R347–R351. Extended report Ann Rheum Dis 2009;68:805–811.
  10. (2008). HUMIRA prescribing information,
  11. (1999). Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial.
  12. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.
  13. (2007). Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis Rheum
  14. (2007). Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis
  15. mg) in active rheumatoid arthritis: a randomized double blind study.
  16. (1993). Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective.
  17. (2007). Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum
  18. (2005). Outcomes generated by patients with rheumatoid arthritis: how important are they? Musculoskeletal Care
  19. (2006). Predictors of response to antiTNF-alpha therapy among patients with rheumatoid arthritis: results fromt h e British Society for Rheumatology Biologics Register. Rheumatology
  20. (2007). Prescribing Information,
  21. (2001). Quality of life profiles in the first years of rheumatoid arthritis: results from the EURIDISS longitudinal study. Arthritis Rheum
  22. (1986). Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis.
  23. (1987). revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum
  24. (1993). SF-36 health survey manual and interpretation guide.
  25. (1994). SF-36 physical and mental health summary scales: a user’s manual.
  26. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.
  27. (2003). Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis
  28. (2007). Updated consensus statement on biological agents for the treatment of rheumatic diseases,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.